Subject: Anticoagulant therapy
Subject: Bleeding
Subject: Cancer
Subject: Mortality
Subject: Recurrences
Subject: Venous thromboembolism
Year: 2016
Type: Article
Title: The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site.
Author: Mahé I
Author: Chidiac J
Author: Bertoletti L
Author: Font C
Author: Trujillo-Santos J
Author: Peris M
Author: Pérez Ductor C
Author: Nieto S
Author: Grandone E
Author: Monreal M
Author: RIETE investigators
Author: Bosevski M
Author: Zdraveska M
Abstract: Background: We hypothesized that the clinical course of venous thromboembolism in patients with active cancer may differ according to the specificities of primary tumor site. Aim and methods: We used data from RIETE (international registry of patients with venous thromboembolism) to compare the clinical venous thromboembolism-related outcomes during the course of anticoagulation in patients with one of the 4 more frequent cancers (breast, prostate, colorectal, or lung cancer). Results: As of September 2014, 3947 cancer patients were recruited, of whom 938 had breast, 629 prostate, 1189 colorectal, and 1191 lung cancer. Overall, 55% had metastatic disease (42%, 36%, 53%, and 72%, respectively). During the course of anticoagulant therapy (mean duration, 139 days), the rate of thromboembolic recurrences was similar to the rate of major bleeding in patients with breast (5.6 [95% confidence interval (CI), 3.8-8.1] vs 4.1 [95% CI, 2.7-5.9] events per 100 patient-years) or colorectal cancer (10 [95% CI, 7.6-13] vs 12 [95% CI, 9.4-15] per 100 patient-years). In contrast, in patients with prostate cancer, the rate of venous thromboembolic recurrences was half the rate of major bleeding (6.9 [95% CI, 4.4-10] vs 13 [95% CI, 9.2-17] events per 100 patient-years), whereas in those with lung cancer, the rate of thromboembolic recurrences was twofold higher than the rate of major bleeding (27 [95% CI, 22-23] vs 11 [95% CI, 8.6-15] per 100 patient-years). Conclusions: Significant differences in the clinical profile of venous thromboembolic-related outcomes were observed according to the site of cancer. These findings suggest the development of cancer-specific anticoagulant strategies as an area for further research.
Publisher: Elsevier
Relation: American Journal of J Mededicine
Identifier: oai:repository.ukim.mk:20.500.12188/29173
Identifier: Mahé I, Chidiac J, Bertoletti L, Font C, Trujillo-Santos J, Peris M, Pérez Ductor C, Nieto S, Grandone E, Monreal M; RIETE investigators. The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. Am J Med. 2017 Mar;130(3):337-347. doi: 10.1016/j.amjmed.2016.10.017.
Identifier: http://hdl.handle.net/20.500.12188/29173Identifier: 10.1016/j.amjmed.2016.10.017
